| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.5043 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.5159 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.5718 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.5885 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6015 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6150 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6455 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6680 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6743 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6885 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.6906 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7170 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7202 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7362 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7380 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7461 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7469 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7538 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7548 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7593 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7632 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7697 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7765 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7792 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7849 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7975 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.7997 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8023 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8073 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8196 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8531 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8675 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8708 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8793 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8855 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8915 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8986 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.8994 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9031 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9038 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9112 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9130 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9211 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9224 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9336 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9439 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9481 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9585 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9704 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9751 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9802 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9925 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 0.9993 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0007 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0055 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0133 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0162 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0189 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0275 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0330 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0644 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0766 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0782 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.0872 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1014 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1105 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1211 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1213 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1314 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1456 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1519 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1546 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1573 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1766 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1834 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1899 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1945 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.1994 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2451 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2483 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2537 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2576 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2629 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2671 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2683 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2721 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.2993 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3133 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3301 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3384 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3415 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3519 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3798 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3817 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.3823 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.4059 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.4068 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.4108 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.4517 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.4931 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.5500 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.5576 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.6100 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.7797 | Peak area | Normal |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 1.7812 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | N-stearoyl-sphingosine (d18:1/18:0)* | 2.1443 | Peak area | Diabetic Neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|